Advertisement

Supportive Care in Cancer

, Volume 25, Issue 3, pp 941–949 | Cite as

Identification of the predictors of cognitive impairment in patients with cancer in palliative care: a prospective longitudinal analysis

  • Geana Paula Kurita
  • Kirstine Skov Benthien
  • Per Sjøgren
  • Stein Kaasa
  • Marianne Jensen Hjermstad
Original Article
  • 373 Downloads

Abstract

Purpose

Studies with neuropsychological assessments in patients with cancer are sparse, and the evidence is very limited regarding their status of cognitive function over time. This study aimed at assessing the prevalence and predictors of cognitive impairment in patients with cancer in palliative care.

Methods

Prospective longitudinal investigation derived from the European Palliative Care Cancer Symptom study (2011–2013) including patients with cancer in palliative care, ≥18 years, and with at least one assessment post-inclusion. For cognitive assessment, a 4-item version of the Mini Mental State Examination was applied at inclusion and after 4 to 16 weeks. Logistic regression model with multiple imputations was applied.

Results

The sample consisted of 1568 patients (50% male, mean age 65.5, 42% with 10–12 years schooling, mean Karnofsky Performance Status—KPS 68%). Longitudinal analysis of the patients with complete MMSE at both assessments (n = 801) showed that 64.5% were not impaired, 12.5% remained cognitively impaired, 11.4% developed impairment, and 11.6% improved. Those who improved cognitively also reported reduced pain intensity and increased appetite. The predictive model (n = 1351) showed that those with low KPS (OR = 1.6, 95% CI 1.0–2.5) most often developed cognitive impairment, while patients with breast cancer (OR = 0.4, 95% CI 0.2–0.7) had lower odds for impairment.

Conclusions

During palliative care, a substantial number of patients remained cognitively impaired or developed cognitive impairment; however, it is noteworthy that improvement was also observed. Physical performance and cancer type may predict cognitive impairment.

Keywords

Neoplasms Cognitive symptoms Cognition Palliative care Quality of life Longitudinal studies 

Notes

Acknowledgements

The EPCCS is a collaborative effort between the European Palliative Care Research Centre (PRC) and the European Association for Palliative Care Research Network (EAPC RN). This study was partially funded by grant no. 6070 from the Joint Research Council at Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital-Trondheim University Hospital.

We would like to thank Morten Aagaard Petersen for assistance with statistical analysis.

Project management: Marianne J. Hjermstad, PRC/NTNU; Stein Kaasa, PRC/NTNU/EAPC RN; Dagny F. Haugen, PRC/NTNU; Pål Klepstad, PRC/NTNU, and Gunnhild Jakobsen PRC/NTNU, Norway; Augusto Caraceni, PRC/EAPC RN, and Cinzia Brunelli, PRC, Italy; Per Sjøgren, EAPC RN, Denmark; Florian Strasser, Switzerland; Barry Laird, PRC/UK.

Project steering committee: Marianne J. Hjermstad, Stein Kaasa, Augusto Caraceni, Cinzia Brunelli, Per Sjøgren, Luc Deliens (EAPC RN, Belgium), Mike Bennett (EAPC RN, UK), David Currow (Australia), Vickie Baracos (Canada).

Core center collaborators: Erik Løhre, St. Olavs Hospital-Trondheim University Hospital; Nina Aass, Oslo University Hospital; Elisabeth Brenne, Øya Helsehus; and Inge Raknes, Haraldsplass Deaconess Hospital, Norway; Geana Kurita, Rigshospitalet and Mogens Groenvold, Bispebjerg Hospital, Denmark; Florian Strasser, Cantonal Hospital St. Gallen, and Cristian Camartin, Kantonspital, Graubünden, Switzerland; Alessandra Pigni, Fondazione IRCCS Istituto Nazionale dei Tumori, and Luigi Cavanna, Oncologia Medica Ospedale Di Piacenza; Adriana Turriziani, Hospice Villa Speranza, Roma; Franco Rizzi, U.O. Complessa di Cure Palliative e Terapia del Dolore. AO ICP, Milan; Laura Piva, Unità di Cure Palliative Azienda Ospedaliera San Paolo, Milan; Federica Aielli, Oncologia Medica Università degli Studi, L’Aquila; and Rondini Ermanno, U.O. Oncologia Medica Arcispedale S. Maria Nuova–IRCCS, Reggio Emilia, Italy; Mike Bennett, Leeds Institute of Health Sciences/University of Leeds; Barry Laird, Western General Hospital Edinburgh/Beatson West of Scotland Cancer Centre, Edinburgh; Andrew Wilcock, Nottingham University Hospitals NHS Trust, Nottingham, and Karen Harvie, Marie Curie Hospice, Glasgow, UK; Maria Nabal, Hospital Universitário Arnau de Vilanova Lleida; Antonio N. Tejedor, Hospital Centro de Cuidados Laguna, Madrid; Josep Porta Sales, Institut Català d’Oncologia, Barcelona; and Marina Martínez, Clinica Universidad De Navarra Pamplona; Spain; Konrad Fassbender, University of Alberta, Canada; David Currow, Flinders University, Australia; Nikolay Yordanov, Comprehensive Cancer Center Vratsa, Bulgaria; Koen Pardon, Ghent University Hospital Flanders, Belgium; Ioseb Abesadze, Cancer Prevention Center, Tblisi, Georgia; Madalena Feio, Instituto Português de Oncologia Francisco Gentil Lisbon, Portugal.

Compliance with ethical standards

The study was approved by The Regional Research Ethics Committee in Medicine, Central Norway (ref. 2010/25945), and registered in the ClinicalTrials.gov database (no. NCT01362816). In addition, approval from ethical committees was obtained at each site. The study was performed according to the Declaration of Helsinki.

Conflict of interest

Stein Kaasa has stock/ownership of Eir Solutions and a consulting/advisory role at Helsinn Healthcare SA. The other authors declare no conflicts of interest.

References

  1. 1.
    Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM, Henrichs M, Carnicke CL Jr (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757CrossRefPubMedGoogle Scholar
  2. 2.
    Ventafridda V, Ripamonti C, DeConno F, Tamburini M, Cassileth BR (1990) Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6:7–11PubMedGoogle Scholar
  3. 3.
    Stufel FC, Holland JC (1991) Delirium in cancer patients. Int Psychogeriatr 3:333–336CrossRefGoogle Scholar
  4. 4.
    Strömgren AS, Goldschimdt D, Groenvold M, Petersen MA, Jensen PT, Pedersen L, Hoermann L, Helleberg C, Sjogren P (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520CrossRefPubMedGoogle Scholar
  5. 5.
    Levine PM, Silberfarb PM, Lipowski ZJ (1978) Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 42:1385–1391CrossRefPubMedGoogle Scholar
  6. 6.
    Kurita GP, Sjøgren P, Ekholm O, Kaasa S, Loge JH, Poviloniene I, Klepstad P (2011) Prevalence and predictors of cognitive dysfunction in opioid treated cancer patients: a multinational study. J Clin Oncol 29:1297–1303CrossRefPubMedGoogle Scholar
  7. 7.
    Massie MJ, Holland J, Glass E (1983) Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048–1050CrossRefPubMedGoogle Scholar
  8. 8.
    Sjøgren P (1997) Psychomotor and cognitive functioning in cancer patients. Acta Anaesthesiol Scand 4:159–161CrossRefGoogle Scholar
  9. 9.
    Ershler WB (2003) Cancer: a disease of the elderly. J Support Oncol 1:5–10PubMedGoogle Scholar
  10. 10.
    Sjøgren P, Olsen AK, Thomsen AB, Dalberg J (2000) Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain 86:237–245CrossRefPubMedGoogle Scholar
  11. 11.
    Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26:102–113CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kurita GP, Lundström S, Sjøgren P, Ekholm O, Christrup L, Davies A, Kaasa S, Klepstad P, Dale O (2015) Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiol Scand 59:1049–1059CrossRefPubMedGoogle Scholar
  13. 13.
    Fayers PM, Hjermstad MJ, Ranhoff AH, Kaasa S, Skogstad L, Klepstad P, Loge JH (2005) Which mini-mental state exam items can be used to screen for delirium and cognitive impairment? J Pain Symptom Manag 30:41–50CrossRefGoogle Scholar
  14. 14.
    Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, EORTC Quality of Life Group (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64CrossRefPubMedGoogle Scholar
  15. 15.
    Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New YorkCrossRefGoogle Scholar
  16. 16.
    Moriarty O, Finn DP (2014) Cognition and pain. Curr Opin Support Palliat Care 8:130–136CrossRefPubMedGoogle Scholar
  17. 17.
    Dong ST, Costa DS, Butow PN, Lovell MR, Agar M, Velikova G, Teckle P, Tong A, Tebbutt NC, Clarke SJ, van der Hoek K, King MT, Fayers PM (2016) Symptom clusters in advanced cancer patients: an empirical comparison of statistical methods and the impact on quality of life. J Pain Symptom Manag 51:88–98CrossRefGoogle Scholar
  18. 18.
    Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS (2014) Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions. EJC Suppl 12:29–40CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    McDonald BC, Saykin AJ (2013) Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations. Brain Imaging Behav 7:374–387CrossRefPubMedGoogle Scholar
  20. 20.
    McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819–828CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    McDonald BC, Conroy SK, Ahles TA (2012) Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 30:2500–2508CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33:4085–4092CrossRefPubMedGoogle Scholar
  23. 23.
    Quaresma M, Coleman MP, Rachet B (2015) 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 385:1206–1218CrossRefPubMedGoogle Scholar
  24. 24.
    Lupien SJ, McEwen BS (1997) The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev 24:1–27CrossRefPubMedGoogle Scholar
  25. 25.
    Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S (2005) Effect of corticosteroids on short-term and long-term memory. Neurology 64:335–337CrossRefPubMedGoogle Scholar
  26. 26.
    Strömgren AS, Sjogren P, Goldschmidt D, Petersen MA, Pedersen L, Hoermann L, Groenvold M (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755CrossRefPubMedGoogle Scholar
  27. 27.
    Lange M, Rigal O, Clarisse B, Giffard B, Sevin E, Barillet M, Eustache F, Joly F (2014) Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treat Rev 40:810–817CrossRefPubMedGoogle Scholar
  28. 28.
    Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Geana Paula Kurita
    • 1
    • 2
  • Kirstine Skov Benthien
    • 1
    • 3
  • Per Sjøgren
    • 1
    • 3
  • Stein Kaasa
    • 4
    • 5
    • 6
  • Marianne Jensen Hjermstad
    • 5
    • 7
  1. 1.Palliative Research Group, Department of OncologyRigshospitalet—Copenhagen University HospitalCopenhagenDenmark
  2. 2.Multidisciplinary Pain Centre, Department of NeuroanaesthesiologyRigshospitalet—Copenhagen University HospitalCopenhagenDenmark
  3. 3.Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of OncologyOslo University HospitalOsloNorway
  5. 5.European Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular MedicineFaculty of Medicine Norwegian University of Science and TechnologyTrondheimNorway
  6. 6.Department of Oncology, Institute of Clinical MedicineFaculty of Medicine, University of OsloOsloNorway
  7. 7.Regional Advisory Unit for Palliative Care, Department of OncologyOslo University HospitalOsloNorway

Personalised recommendations